%0 Journal Article
%T Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers
%A Cheng-Bo Han
%A Jia-He Zheng
%A Jian-Zhu Zhao
%A Jie-Tao Ma
%A Le-Tian Huang
%A Li Sun
%A Rui Cao
%A Shu-Ling Zhang
%A Wei Jing
%A Xiang-Yan Zhang
%A Yan-Hua Zhen
%A Yi-Jia Guo
%J SCIE-indexed Journal
%D 2020
%R 10.21037/jtd.2019.12.128
%X Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases (1). For advanced NSCLC with epidermal growth factor receptor (EGFR) mutation, EGFR tyrosine kinase inhibitors (EGFR-TKIs) serve as standard first-line therapies with a response rate of over 70% and a median progression-free survival (PFS) of 9¨C13 months (2,3). However, patients receiving the EGFR-TKI treatment almost inevitably develop disease progression due to primary or secondary drug resistance. The mechanism of resistance is complicated, with EGFR T790M accounting for approximately 50% of its emergence. Mesenchymal-epithelial transition amplification, epithelial-mesenchymal transition (EMT), and small cell transformation can also lead to drug resistance (4). Once tumor cells acquire the properties of EMT, their invasive ability and metastasis will be enhanced, thereby resulting in drug resistance (5)
%U http://jtd.amegroups.com/article/view/36403/html